Wisconsin Alumni Research Foundation

Pharmaceuticals & Vitamin D
Pharmaceuticals Vitamin D
New Broad-Spectrum Antibiotics
WARF: P140321US02

Inventors: Douglas Weibel, Katherine Hurley, Katherine Faulkner

The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in developing small molecule compounds that interfere with bacterial membranes.
The rise of antibiotic-resistant bacteria represents a potential health crisis. Some antibiotics (e.g., quinolones and fluoroquinolones) are losing their effectiveness while others simply don’t work against Gram-negative bacteria. This class of bacteria includes strains responsible for food poisoning, urinary tract infections, pneumonia, cystic fibrosis and sepsis.
The Invention
A UW–Madison researcher and collaborators have identified an antibiotic compound effective against many drug-resistant, Gram-negative and Gram-positive bacteria. The compound (5-nonyloxytryptamine) and its analogs are small molecule inhibitors that interfere with the bacterial membrane and prevent replication.

The compound has been reported as an anticancer drug but was not previously shown to have antimicrobial properties. It was identified by searching for compounds that cause E. coli bacteria to lack a copy of the chromosome following cell division.
  • Antibiotic to treat infections and inhibit bacterial growth
  • Bacteria targets include Escherichia coli, Salmonella, Shigella, Bacillus, Listeria, Staphylococcus and Streptococcus species.
  • Topical and potentially systemic usage
Key Benefits
  • Broad-spectrum weapon against Gram-negative, Gram-positive and antibiotic-resistant bacteria
Stage of Development
The compound has been tested against a broad panel of human pathogens with promising results.
Additional Information
For More Information About the Inventors
Related Intellectual Property
For current licensing status, please contact Rafael Diaz at [javascript protected email address] or 608-960-9847